Sbiera Silviu, Kunz Meik, Weigand Isabel, Deutschbein Timo, Dandekar Thomas, Fassnacht Martin
Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, D-97080 Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University of Würzburg, D-97080 Würzburg, Germany.
Cancers (Basel). 2019 Nov 8;11(11):1761. doi: 10.3390/cancers11111761.
Cushing's disease (CD) is a rare condition caused by adrenocorticotropic hormone (ACTH)-producing adenomas of the pituitary, which lead to hypercortisolism that is associated with high morbidity and mortality. Treatment options in case of persistent or recurrent disease are limited, but new insights into the pathogenesis of CD are raising hope for new therapeutic avenues. Here, we have performed a meta-analysis of the available sequencing data in CD to create a comprehensive picture of CD's genetics. Our analyses clearly indicate that somatic mutations in the deubiquitinases are the key drivers in CD, namely USP8 (36.5%) and USP48 (13.3%). While in USP48 only Met415 is affected by mutations, in USP8 there are 26 different mutations described. However, these different mutations are clustering in the same hotspot region (affecting in 94.5% of cases Ser718 and Pro720). In contrast, pathogenic variants classically associated with tumorigenesis in genes like TP53 and BRAF are also present in CD but with low incidence (12.5% and 7%). Importantly, several of these mutations might have therapeutic potential as there are drugs already investigated in preclinical and clinical setting for other diseases. Furthermore, network and pathway analyses of all somatic mutations in CD suggest a rather unified picture hinting towards converging oncogenic pathways.
库欣病(CD)是一种由垂体分泌促肾上腺皮质激素(ACTH)的腺瘤引起的罕见病症,会导致高皮质醇血症,且与高发病率和死亡率相关。对于持续性或复发性疾病,治疗选择有限,但对CD发病机制的新见解为新的治疗途径带来了希望。在此,我们对CD中可用的测序数据进行了荟萃分析,以全面了解CD的遗传学特征。我们的分析清楚地表明,去泛素化酶中的体细胞突变是CD的关键驱动因素,即USP8(36.5%)和USP48(13.3%)。虽然在USP48中只有Met415受突变影响,但在USP8中有26种不同的突变被描述。然而,这些不同的突变聚集在同一热点区域(94.5%的病例影响Ser718和Pro720)。相比之下,经典的与肿瘤发生相关的致病变体,如TP53和BRAF基因中的变体,在CD中也存在,但发生率较低(分别为12.5%和7%)。重要的是,其中一些突变可能具有治疗潜力,因为已经有针对其他疾病在临床前和临床环境中研究的药物。此外,对CD中所有体细胞突变的网络和通路分析表明,存在一个相当统一的图景,暗示致癌通路趋于一致。